The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment

Radiotherapy and Oncology

Volumn 92, Issue 3, 2009, Pages 399-404

  Theys, Jan ^a   Jutten, Barry ^a   Dubois, Ludwig ^a   Rouschop, Kasper M A ^a   Chiu, Roland K ^b   Li, Younan ^a   Paesmans, Kim ^a   Lambin, Philippe ^a   Lammering, Guido ^a   Wouters, Bradly G ^a,c,d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

EGFRvIII; Epidermal growth factor receptor (EGFR); Hypoxia; Microenvironment; Tumour

Indexed keywords

DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; ENVIRONMENTAL STRESS; FEMALE; GENE DELETION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SURVIVAL; DOXYCYCLINE; ENVIRONMENT; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; LINEAR MODELS; MICE; MICE, NUDE; MUTATION; PROBABILITY; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; STRESS, PHYSIOLOGICAL; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 70249121467     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.06.017     Document Type: Article

References (25)

1. Herbst R.S. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 (2004) 21-26
2. Bussink J., Kaanders J.H., and Van der Kogel A.J. Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy. Radiother Oncol 82 (2007) 10-17
3. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354
4. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
5. Baumann M., Krause M., Dikomey E., et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83 (2007) 238-248
6. Lammering G. Molecular predictor and promising target: will EGFR now become a star in radiotherapy?. Radiother Oncol 74 (2005) 89-91
7. Astsaturov I., Cohen R.B., and Harari P.M. Clinical application of EGFR inhibitors in head and neck squamous cell cancer. Cancer Treat Res 139 (2008) 135-152
8. Krause M., and Baumann M. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer Metastasis Rev 27 (2008) 387-402
9. Wong A.J., Ruppert J.M., Bigner S.H., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89 (1992) 2965-2969
10. Gan H.K., Kaye A.H., and Luwor R.B. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci (2009)
11. Bigner S.H., Humphrey P.A., Wong A.J., et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50 (1990) 8017-8022
12. Wouters B.G., and Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8 (2008) 851-864
13. Weppler S.A., Li Y., Dubois L., et al. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother Oncol 83 (2007) 333-339
14. Aerts H.J., Dubois L., Hackeng T.M., et al. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiother Oncol 83 (2007) 326-332
15. Johns T.G., Perera R.M., Vernes S.C., et al. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 13 (2007) 1911-1925
16. Tang C.K., Gong X.Q., Moscatello D.K., Wong A.J., and Lippman M.E. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 60 (2000) 3081-3087
17. Prigent S.A., Nagane M., Lin H., et al. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271 (1996) 25639-25645
18. Huang P.H., Mukasa A., Bonavia R., et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104 (2007) 12867-12872
19. Klingler-Hoffmann M., Bukczynska P., and Tiganis T. Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int J Cancer 105 (2003) 331-339
20. Narita Y., Nagane M., Mishima K., Huang H.J., Furnari F.B., and Cavenee W.K. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 62 (2002) 6764-6769
21. Ramnarain D.B., Park S., Lee D.Y., et al. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 66 (2006) 867-874
22. Grandal M.V., Zandi R., Pedersen M.W., Willumsen B.M., van Deurs B., and Poulsen H.S. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 28 (2007) 1408-1417
23. Wang Y., Roche O., Yan M.S., et al. Regulation of endocytosis via the oxygen-sensing pathway. Nat Med 15 (2009) 319-324
24. Franovic A., Gunaratnam L., Smith K., Robert I., Patten D., and Lee S. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci USA 104 (2007) 13092-13097
25. Lammering G., Hewit T.H., Holmes M., et al. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res 10 (2004) 6732-6743